Vumerity Euroopan unioni - unkari - EMA (European Medicines Agency)

vumerity

biogen netherlands b.v. - diroximel fumarate (biib098) - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Dimethyl fumarate Teva Euroopan unioni - unkari - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimetil-fumarát - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunszuppresszánsok - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Mylan Euroopan unioni - unkari - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - dimetil-fumarát - a sclerosis multiplex, a relapszáló-remittáló - immunszuppresszánsok - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evrysdi Euroopan unioni - unkari - EMA (European Medicines Agency)

evrysdi

roche registration gmbh  - risdiplam - izomsorvadás, spinal - egyéb gyógyszerek az izom-csontrendszer rendellenességeihez - evrysdi is indicated for the treatment of 5q spinal muscular atrophy (sma) in patients with a clinical diagnosis of sma type 1, type 2 or type 3 or with one to four smn2 copies.